Antipsychotics in the early stage of development

Current Opinion in Psychiatry

Volumn 22, Issue 3, 2009, Pages 326-330

  Biedermann, Falko ^a   Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotics; Development; Schizophrenia

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACP 104; ASENAPINE; BIFEPRUNOX; CELECOXIB; CYCLOSERINE; DMXB A; DOPAMINE; DOPAMINE 2 RECEPTOR; ESTRADIOL; GALANTAMINE; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; ILOPERIDONE; ISPRONICLINE; MEMANTINE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; OMEGA 3 FATTY ACID; PIMAVANSERIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; SARCOSINE; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; XANOMELINE;

AKATHISIA; ALZHEIMER DISEASE; ANXIETY; CENTRAL NERVOUS SYSTEM; CLINICAL RESEARCH; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; NEGATIVE SYNDROME; NEUROTRANSMISSION; POLYPHARMACY; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DOPAMINE; GLUTAMIC ACID; HUMANS; KETAMINE; PHENCYCLIDINE; RECEPTORS, CHOLINERGIC; RECEPTORS, MUSCARINIC; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEVERITY OF ILLNESS INDEX; SYNAPTIC TRANSMISSION;

EID: 62349102044     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328329cd73     Document Type: Review

References (36)

1. Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 1999; 84:193-196. [review]. (Pubitemid 29205279)
2. George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007; 93:42-50. (Pubitemid 46817947)
3. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001; 25:904-914. (Pubitemid 34031895)
4. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008; 28 (2 Suppl 1):S12-S19.
5. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28 (2 Suppl 1):S29-S35.
6. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009; 23:65-73.
7. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007; 68:1492-1500. (Pubitemid 350073395)
8. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose- finding study. Psychopharmacology (Berl) 2008; 200:317-331.
9. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 2008; 13:479-495.
10. Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008; 9:3251-3259.
11. Suckling CJ, Murphy JA, Khalaf AI, et al. M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds. Bioorg Med Chem Lett 2007; 17:2649-2655.
12. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26:365-384. [review].
13. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164:1593-1602.
14. Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008; 258:16-27; Review.
15. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63:9-12. (Pubitemid 350234891)
16. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebocontrolled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2008. http://www.nature.com/ npp/journal/vaop/ncurrent/abs/npp20082
17. Svensson L, Zhang J, Johannessen K, Engel JA. Effect of local infusion of glutamate analogues into the nucleus accumbens of rats: an electrochemical and behavioural study. Brain Res 1994; 643:155-161. (Pubitemid 24115089)
18. Hu G, Duffy P, Swanson C, et al. The regulation of dopamine transmission by metabotropic glutamate receptors. J Pharmacol Exp Ther 1999; 289:412-416. (Pubitemid 29156057)
19. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13:1102-1107. (Pubitemid 47517511)
20. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008; 33:465-472.
21. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21:484-487. (Pubitemid 32937430)
22. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004; 174:54-64. [review]. (Pubitemid 38925091)
23. Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003; 28:542-551.
24. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63:630-638. (Pubitemid 43848294)
25. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165:1040-1047.
26. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebocontrolled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007; 22:63-68. (Pubitemid 46254865)
27. Dyer MA, Freudenreich O, Culhane MA, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008; 102:88-95.
28. Dunbar G, Boeijinga PH, Demazières A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007; 191:919-929.
29. Astra Zeneca and Targacept announce top-line results from phase IIb study of AZD3480 in cognitive dysfunction in schizophrenia; 2008.
30. Dean B, McLeod M, Keriakous D, et al. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7:1083-1091. (Pubitemid 36044267)
31. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995; 35:800-806.
32. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165:1033-1039.
33. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65:955-960.
34. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 2008; 45:19-25. [review].
35. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12:206-220. (Pubitemid 46160985)
36. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90:179-185. (Pubitemid 46177578)